1
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Boehringer Ingelheim International, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, DAVIS Steven G, November 5, 2009: WO/2009/134400 (46 worldwide citation)

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, lo1, lo2, lo5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibit ...


2
Claremon David A, He Wei, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Zhao Wei, Zhuang Linghang, Cacatian Salvacion, Leftheris Katerina: Cyclic inhibitors of 11β-hydroxysteriod dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, He Wei, Mcgeehan Gerard, Singh Suresh B, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Zhao Wei, Zhuang Linghang, Cacatian Salvacion, Leftheris Katerina, DAVIS Steven G, February 5, 2009: WO/2009/017664 (33 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modu ...


3
Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, Eckhardt Matthias: Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Boehringer Ingelheim International, Claremon David A, Zhuang Linghang, Leftheris Katerina, Tice Colin M, Xu Zhenrong, Ye Yuanjie, Singh Suresh B, Cacatian Salvacion, Zhao Wei, Himmelsbach Frank, Eckhardt Matthias, DAVIS Steven G, November 5, 2009: WO/2009/134392 (28 worldwide citation)

This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in m ...


4
Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei: Cyclic urea inhibitors of 11β -hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei, DAVIS Steven G, May 14, 2009: WO/2009/061498 (27 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih)1 (Ij), (Ik), (II1-3). (Im1-3), (In1-3), (lo1-2), (Ip1-6), (Iq1-6), (Ir1-6) and (Is1-2), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful fo ...


5
Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei: Cyclic urea inhibitors of hb-hydroxysteroid dehydrogenase 1. Vitae Pharmaceutical, Claremon David A, Zhuang Linghang, Tice Colin M, Ye Yuanjie, He Wei, Singh Suresh B, Xu Zhenrong, Cacatian Salvacion, Zhao Wei, DAVIS Steven G, June 18, 2009: WO/2009/075835 (23 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The inve ...


6
Claremon David A, Zhuang Linghang, Ye Yuanjie, Singh Suresh B, Tice Colin M, Cacatian Salvacion: Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1. Vitae Pharmaceuticals, Claremon David A, Zhuang Linghang, Ye Yuanjie, Singh Suresh B, Tice Colin M, Cacatian Salvacion, DAVIS Steven G, July 30, 2009: WO/2009/094169 (23 worldwide citation)

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie),(If), (Ig), (Ih), (Ii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibiti ...


7
Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, Wery Jean Pierre: Diaminoalkane aspartic protease inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Zhao Wei, Simpson Robert D, Singh Suresh B, Flaherty Patrick T, Wery Jean Pierre, DAVIS Steven G, April 20, 2006: WO/2006/042150 (13 worldwide citation)

Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the ...


8
Claremon David A, Singh Suresh B, Tice Colin M, Ye Yuanjie, Cacatian Salvacion, He Wei, Simpson Robert, Xu Zhenrong, Zhao Wei: Inhibitors of 11β -hydroxysteroid dehydrogenase type 1. Vitae Pharmaceuticals, Claremon David A, Singh Suresh B, Tice Colin M, Ye Yuanjie, Cacatian Salvacion, He Wei, Simpson Robert, Xu Zhenrong, Zhao Wei, DAVIS Steven G, February 28, 2008: WO/2008/024497 (11 worldwide citation)

This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β- HSDl in mammals. The invention further rel ...


9
Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Simpson Robert D, Singh Suresh B, Zhao Wei, Flaherty Patrick T: Aspartic protease inhibitors. Vitae Pharmaceuticals, Baldwin John J, Claremon David A, Tice Colin, Cacatian Salvacion, Dillard Lawrence W, Ishchenko Alexey V, Yuan Jing, Xu Zhenrong, Mcgeehan Gerard, Simpson Robert D, Singh Suresh B, Zhao Wei, Flaherty Patrick T, ABELLEIRA Susan M, June 21, 2007: WO/2007/070201 (8 worldwide citation)

The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions compris ...


10